CBL anticorps (pTyr731) (Biotin)

N° du produit ABIN683970

Cet anticorps anti-CBL est un anticorps Lapin Polyclonal détectant CBL dans ELISA, IHC (p) et IHC (fro). Adapté pour Humain.

Aperçu rapide pour CBL anticorps (pTyr731) (Biotin) (ABIN683970)

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CBL est conjugé à/à la Biotin

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-CBL anticorps (Biotin)

Épitope: pTyr731

Homologie: Human,Mouse,Rat,Dog,Cow,Pig

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr731

Isotype: IgG

Information d'application

Indications d'application: IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur CBL

Antigène: CBL (Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL))

Autre désignation: CBL2

Sujet:

Synonyms: C CBL Tyr731, CBL2 Tyr731, CBL2 Tyr731, p-CBL2 Tyr731, p-CBL2 Y731, C CBL, Cas-Br-M murine ecotropic retroviral transforming sequence, Casitas B lineage lymphoma proto oncogene, CBL 2,E3 ubiquitin protein ligase CBL, Oncogene CBL2, Proto oncogene c CBL, RGD1561386, RING finger protein 55, RNF55v Signal transduction protein CBL, 4732447J05Rik, CBL_HUMAN.

Background: The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas and myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src and Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL?s interaction with downstream targets of tyrosine kinases, such as PI 3K and Vav.

ID gène: 867

Pathways: TCR Signaling, Interferon-gamma Pathway, EGFR Signaling Pathway, EGFR Downregulation, VEGFR1 Specific Signals